Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Abrams

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
Journal of Hepatocellular Carcinoma|July 29, 2025
A Summary of the HCC-CARE Symposium: Collaborative Approaches to Reaching Equity in Hepatocellular Carcinoma in Boston by 2030Kelsey S Lau-Min, Thomas Abrams, Andrea Bullock, et al.
Neurobiology of Learning and Memory|October 16, 2008
Habituation revisited: an updated and revised description of the behavioral characteristics of habituationCatharine H Rankin, Thomas Abrams, Robert J Barry, et al.
JNCI Cancer Spectrum|February 25, 2020
Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer SurvivorsJeffrey A Meyerhardt, Melinda L Irwin, Lee W Jones, et al.
The Oncologist|April 13, 2013
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin, Kimmie Ng, Andrew X Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025
Phase II trial of cabozantinib in combination with nivolumab for advanced extrapancreatic neuroendocrine tumors (epNET)Kimberly J Perez, Nora Horick, Joanna Baginska, et al.
The Oncologist|February 22, 2023
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic CancerKimberly Perez, Anna M Chiarella, James M Cleary, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 11, 2023
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023Al B Benson, Michael I D'Angelica, Thomas Abrams, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 10, 2025
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyAl B Benson, Michael I D'Angelica, Thomas Abrams, et al.
Nature Cancer|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trialKimberly J Perez, Andressa Dias Costa, Alexander Jordan, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
Journal of Hepatocellular Carcinoma|July 29, 2025
A Summary of the HCC-CARE Symposium: Collaborative Approaches to Reaching Equity in Hepatocellular Carcinoma in Boston by 2030Kelsey S Lau-Min, Thomas Abrams, Andrea Bullock, et al.
Neurobiology of Learning and Memory|October 16, 2008
Habituation revisited: an updated and revised description of the behavioral characteristics of habituationCatharine H Rankin, Thomas Abrams, Robert J Barry, et al.
JNCI Cancer Spectrum|February 25, 2020
Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer SurvivorsJeffrey A Meyerhardt, Melinda L Irwin, Lee W Jones, et al.
The Oncologist|April 13, 2013
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin, Kimmie Ng, Andrew X Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025
Phase II trial of cabozantinib in combination with nivolumab for advanced extrapancreatic neuroendocrine tumors (epNET)Kimberly J Perez, Nora Horick, Joanna Baginska, et al.
The Oncologist|February 22, 2023
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic CancerKimberly Perez, Anna M Chiarella, James M Cleary, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 11, 2023
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023Al B Benson, Michael I D'Angelica, Thomas Abrams, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 10, 2025
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyAl B Benson, Michael I D'Angelica, Thomas Abrams, et al.
Nature Cancer|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trialKimberly J Perez, Andressa Dias Costa, Alexander Jordan, et al.
Pageof 2